Baudax Bio shares are trading higher after the company announced it was granted orphan drug designation by the FDA for TI-168 for the treatment of Hemophilia A with inhibitors.
Portfolio Pulse from Benzinga Newsdesk
Baudax Bio has been granted orphan drug designation by the FDA for TI-168, a treatment for Hemophilia A with inhibitors. This news has led to a rise in the company's share prices.
September 28, 2023 | 12:48 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Baudax Bio's stock is trading higher following the FDA's orphan drug designation for its Hemophilia A treatment, TI-168.
The FDA's orphan drug designation is a significant regulatory milestone that can lead to faster approval and market exclusivity, which can drive sales and profits. This positive news is likely to boost investor confidence and drive up Baudax Bio's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100